Galecto, Inc.
  • Welcome
  • About
    • Board
    • Management
    • Founders
    • Clinical Advisory Boards
      • IPF
      • NASH
      • Myelofibrosis
    • Presentations
  • Diseases
    • Fibrosis
    • Cancer
    • Literature
  • Pipeline
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Careers
  • Contact
  • Menu

Jakob Dynnes Hansen

Hans T. Schambye

Anders Pedersen


Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.



Follow us





Board


Management


Founders

Copyright Galecto, Inc 2020 © 
CookiesPrivacy Policy
Scroll to top
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish
OK Reject Read More
Privacy & Cookies Policy
Necessary
Always Enabled